low-intensity statin plus ezetimibe
ApprovedSmall molecule
low-intensity statin plus ezetimibe is one of 37 small molecule programs targeting Diabetes Mellitus. It is currently in Approved.
1
Indications
1
Total Trials
1
Active Trials
36
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
286 competitors in Diabetes Mellitus
#DrugCompanyPhaseTrials
1LY2605541
Eli LillyPhase 3
Volinanserin
SanofiPhase 3
low-intensity statin plus ezetimibe
SSeung-Whan Lee, M.D., Ph.D.
Approved
Trulicity
Eli LillyPreclinical
Byetta
AstraZenecaPreclinical
Galvus
NovartisPreclinical
NOVOLIN R
Novo NordiskPreclinical
Edarbi
TakedaPreclinical
Paxil CR
GSKPreclinical
Simponi
Johnson & JohnsonPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- SSeung-Whan Lee, M.D., Ph.D.